TY - JOUR
T1 - Conjugate meningococcal serogroup A and C vaccine
T2 - Reactogenicity and immunogenicity in United Kingdom infants
AU - Fairley, Christopher K.
AU - Begg, Norman
AU - Borrow, Raymond
AU - Fox, Andrew J.
AU - Jones, Dennis M.
AU - Cartwright, Keith
PY - 1996/1/1
Y1 - 1996/1/1
N2 - The reactogenicity and immunogenicity of a serogroup A and C meningococcal polysaccharide-CRM197 conjugate vaccine was evaluated in 58 infants who received three doses at 2, 3, and 4 months of age. The conjugate vaccine produced few systemic side effects, and local reactions were significantly less common than those produced by the routine vaccinations. The prevaccination geometric mean titers (GMTs) of A and C polysaccharide antibodies were, respectively, 2.8 and 0.6 μg/mL, rising to 21.5 and 38.5 μg/mL by 1 month after the third dose (age 5 months) and falling to 3.1 and 2.2 μg/mL by 14 months of age. Prevaccination serum bactericidal titers against 2 serogroup C meningococci strains were <1/4 in 49 of 52 infants, rising to a GMT of 1/3082 at 1 month after the third dose and falling by age 14 months to a GMT of 1/10. Thus, this meningococcal conjugate vaccine proved to be safe and immunogenic, inducing high levels of anti-C polysaccharide antibodies that were bactericidal in young infants.
AB - The reactogenicity and immunogenicity of a serogroup A and C meningococcal polysaccharide-CRM197 conjugate vaccine was evaluated in 58 infants who received three doses at 2, 3, and 4 months of age. The conjugate vaccine produced few systemic side effects, and local reactions were significantly less common than those produced by the routine vaccinations. The prevaccination geometric mean titers (GMTs) of A and C polysaccharide antibodies were, respectively, 2.8 and 0.6 μg/mL, rising to 21.5 and 38.5 μg/mL by 1 month after the third dose (age 5 months) and falling to 3.1 and 2.2 μg/mL by 14 months of age. Prevaccination serum bactericidal titers against 2 serogroup C meningococci strains were <1/4 in 49 of 52 infants, rising to a GMT of 1/3082 at 1 month after the third dose and falling by age 14 months to a GMT of 1/10. Thus, this meningococcal conjugate vaccine proved to be safe and immunogenic, inducing high levels of anti-C polysaccharide antibodies that were bactericidal in young infants.
UR - http://www.scopus.com/inward/record.url?scp=0029852070&partnerID=8YFLogxK
U2 - 10.1093/infdis/174.6.1360
DO - 10.1093/infdis/174.6.1360
M3 - Article
C2 - 8940235
AN - SCOPUS:0029852070
VL - 174
SP - 1360
EP - 1363
JO - The Journal of Infectious Diseases
JF - The Journal of Infectious Diseases
SN - 0022-1899
IS - 6
ER -
